<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="emergency-medicine-and-critical-care" lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher">JOHS</journal-id>
      <journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
      <journal-title-group>
        <journal-title>Journal of HealthCare Sciences</journal-title>
        <abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2231-2196</issn>
      <issn pub-type="opub">0975-5241</issn>
      <publisher>
        <publisher-name>Radiance Research Academy</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">283</article-id>
      <article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2024.40805</article-id>
      <article-id pub-id-type="doi-url"/>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Emergency Medicine and Critical Care</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Assessing the Role of Pulmonary Vasodilators in Emergency Medicine: A Systematic Review&#13;
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Alotaibi</surname>
            <given-names>Malak Fahad</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alghorry</surname>
            <given-names>Nouf Sajer</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="ppub">
        <day>7</day>
        <month>08</month>
        <year>2024</year>
      </pub-date>
      <volume>4</volume>
      <issue>8</issue>
      <fpage>296</fpage>
      <lpage>310</lpage>
      <permissions>
        <copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
        <copyright-year>2009</copyright-year>
        <license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Background: Pulmonary vasodilators play a crucial role in emergency medicine by providing rapid relief and stabilization in acute pulmonary conditions characterized by increased pulmonary vascular resistance and hemodynamic instability. These medications act to dilate blood vessels in the lungs, thereby reducing pulmonary artery pressure and improving blood flow to optimize oxygenation and cardiac function.&#13;
&#13;
Methodology: In this systematic review we aim to investigate the role of pulmonary vasodilators in emergency medicine settings, focusing on their efficacy and safety in managing various conditions. The inclusion criteria for this systematic review encompassed studies published in peer-reviewed journals focusing on human subjects treated in emergency departments using pulmonary vasodilators. The Newcastle-Ottawa Scale was employed to assess the quality and potential biases in the observational studies included in this review, while for randomized trials, RoB 2: A revised Cochrane risk-of-bias tool for randomized trials was used.&#13;
&#13;
Results: We incorporated a total of 8 studies encompassing 1648 patients, published between 2002 and 2022. Diverse conditions reported in emergency settings were hypoxemic respiratory failure, sickle cell disease, eczema, chronic sinusitis and gastroesophageal reflux, asthma, respiratory symptoms of SARS-CoV-2 infection, acute pulmonary embolism, pulmonary edema, pulmonary arterial hypertension, sepsis, and acute respiratory distress syndrome. Inhaled epoprostenol, nitric oxide, bronchodilator, and intravenous nitroglycerine, along with bosentan and sildenafil, were used for the management of these conditions. The outcomes varied, as the majority of the included studies reported successful management and improvement in the condition, while few other studies did not observe any significant differences. &#13;
&#13;
Conclusion: The review highlights the significant impact of pulmonary vasodilators in the management of various conditions encountered or treated in emergency medicine settings. Future studies should focus on personalized approaches to therapy, alternative delivery methods, and the impact of pulmonary vasodilators on patient-centred outcomes, ultimately informing evidence-based practice and enhancing patient care in emergency medicine settings.&#13;
</p>
      </abstract>
      <kwd-group>
        <kwd>pulmonary</kwd>
        <kwd> vasodilators</kwd>
        <kwd> management</kwd>
        <kwd> emergency</kwd>
        <kwd> medicine</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>